UK Markets closed

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.64-0.28 (-2.61%)
As of 1:17PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close10.92
Open11.08
Bid10.43 x 800
Ask10.44 x 800
Day's range9.69 - 11.19
52-week range1.58 - 12.90
Volume6,035,382
Avg. volume7,869,415
Market cap1.888B
Beta (5Y monthly)2.82
PE ratio (TTM)N/A
EPS (TTM)-1.09
Earnings date04 May 2021 - 10 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.78
  • Why BioCryst Pharmaceuticals Stock Is Popping Today
    Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Popping Today

    Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are rising sharply today following bullish commentary from a Wall Street analyst. The biopharmaceutical company's stock was up by 9.2% as of 1:11 p.m. EST, after jumping by as much as 10.6% earlier on Monday. Cowen analyst Ken Cacciatore initiated coverage on BioCryst stock with an outperform (buy) rating.

  • Why BioCryst Pharmaceuticals Stock Is Falling Today
    Motley Fool

    Why BioCryst Pharmaceuticals Stock Is Falling Today

    BioCryst Pharmaceuticals (NASDAQ: BCRX) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results. BioCryst's shares were down by 8.4% as of 1:53 p.m. EST. BioCryst's total revenue for the fourth quarter ending Dec. 31 was roughly $4 million, down from the $39.7 million in revenue recorded during the year-ago period.

  • BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript
    Motley Fool

    BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst fourth-quarter 2020 earnings call. Participating with me today are CEO Jon Stonehouse, CFO Anthony Doyle, Chief Medical Officer, Dr.